Current state of quality of life and patient-reported outcomes research

5th EORTC Quality of Life in Cancer Clinical Trials Conference Faculty

Research output: Contribution to journalArticle

Abstract

The 5th EORTC Quality of Life in Cancer Clinical Trials Conference presented the current state of quality of life and other patient-reported outcomes (PROs) research from the perspectives of researchers, regulators, industry representatives, patients and patient advocates and health care professionals. A major theme was the assessment of the burden of cancer treatments, and this was discussed in terms of regulatory challenges in using PRO assessments in clinical trials, patients’ experiences in cancer clinical trials, innovative methods and standardisation in cancer research, innovative methods across the disease sites or populations and cancer survivorship. Conferees demonstrated that PROs are becoming more accepted and major efforts are ongoing internationally to standardise PROs measurement, analysis and reporting in trials. Regulators are keen to collaborate with all stakeholders to ensure that the right questions are asked and the right answers are communicated. Improved technology and increased flexibility of measurement instruments are making PROs data more robust. Patients are being encouraged to be patient partners. International collaborations are essential, because this work cannot be accomplished on a national level.

Original languageEnglish (US)
Pages (from-to)55-63
Number of pages9
JournalEuropean Journal of Cancer
Volume121
DOIs
StatePublished - Nov 2019

Fingerprint

Quality of Life
Outcome Assessment (Health Care)
Clinical Trials
Neoplasms
Patient Outcome Assessment
Patient Advocacy
Patient Care
Industry
Survival Rate
Research Personnel
Patient Reported Outcome Measures
Technology
Delivery of Health Care
Research
Population
Therapeutics

Keywords

  • Cancer patients
  • Cancer survivorship
  • Cancer treatment
  • Patient-reported outcomes
  • Quality of life
  • Symptom assessments

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

5th EORTC Quality of Life in Cancer Clinical Trials Conference Faculty (2019). Current state of quality of life and patient-reported outcomes research. European Journal of Cancer, 121, 55-63. https://doi.org/10.1016/j.ejca.2019.08.016

Current state of quality of life and patient-reported outcomes research. / 5th EORTC Quality of Life in Cancer Clinical Trials Conference Faculty.

In: European Journal of Cancer, Vol. 121, 11.2019, p. 55-63.

Research output: Contribution to journalArticle

5th EORTC Quality of Life in Cancer Clinical Trials Conference Faculty 2019, 'Current state of quality of life and patient-reported outcomes research', European Journal of Cancer, vol. 121, pp. 55-63. https://doi.org/10.1016/j.ejca.2019.08.016
5th EORTC Quality of Life in Cancer Clinical Trials Conference Faculty. Current state of quality of life and patient-reported outcomes research. European Journal of Cancer. 2019 Nov;121:55-63. https://doi.org/10.1016/j.ejca.2019.08.016
5th EORTC Quality of Life in Cancer Clinical Trials Conference Faculty. / Current state of quality of life and patient-reported outcomes research. In: European Journal of Cancer. 2019 ; Vol. 121. pp. 55-63.
@article{fe907f044c3043968cfaefce32bf8729,
title = "Current state of quality of life and patient-reported outcomes research",
abstract = "The 5th EORTC Quality of Life in Cancer Clinical Trials Conference presented the current state of quality of life and other patient-reported outcomes (PROs) research from the perspectives of researchers, regulators, industry representatives, patients and patient advocates and health care professionals. A major theme was the assessment of the burden of cancer treatments, and this was discussed in terms of regulatory challenges in using PRO assessments in clinical trials, patients’ experiences in cancer clinical trials, innovative methods and standardisation in cancer research, innovative methods across the disease sites or populations and cancer survivorship. Conferees demonstrated that PROs are becoming more accepted and major efforts are ongoing internationally to standardise PROs measurement, analysis and reporting in trials. Regulators are keen to collaborate with all stakeholders to ensure that the right questions are asked and the right answers are communicated. Improved technology and increased flexibility of measurement instruments are making PROs data more robust. Patients are being encouraged to be patient partners. International collaborations are essential, because this work cannot be accomplished on a national level.",
keywords = "Cancer patients, Cancer survivorship, Cancer treatment, Patient-reported outcomes, Quality of life, Symptom assessments",
author = "{5th EORTC Quality of Life in Cancer Clinical Trials Conference Faculty} and Andrew Bottomley and Reijneveld, {Jaap C.} and Michael Koller and Henning Flechtner and Tomaszewski, {Krzysztof A.} and Eva Greimel and Ganz, {Patricia A.} and Jolie Ringash and Daniel O'Connor and Kluetz, {Paul G.} and Giovanni Tafuri and Mogens Gr{\o}nvold and Claire Snyder and Carolyn Gotay and Fallowfield, {Dame Lesley} and Kathi Apostolidis and Roger Wilson and Richard Stephens and Holger Sch{\"u}nemann and Melanie Calvert and Bernhard Holzner and Musoro, {Jammbe Z.} and Sally Wheelwright and Francesca Martinelli and Dueck, {Amylou C.} and Madeline Pe and Corneel Coens and Galina Velikova and Dagmara Kuliś and Taphoorn, {Martin J.B.} and Darlington, {Anne Sophie} and Ian Lewis and {van de Poll-Franse}, Lonneke",
year = "2019",
month = "11",
doi = "10.1016/j.ejca.2019.08.016",
language = "English (US)",
volume = "121",
pages = "55--63",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Current state of quality of life and patient-reported outcomes research

AU - 5th EORTC Quality of Life in Cancer Clinical Trials Conference Faculty

AU - Bottomley, Andrew

AU - Reijneveld, Jaap C.

AU - Koller, Michael

AU - Flechtner, Henning

AU - Tomaszewski, Krzysztof A.

AU - Greimel, Eva

AU - Ganz, Patricia A.

AU - Ringash, Jolie

AU - O'Connor, Daniel

AU - Kluetz, Paul G.

AU - Tafuri, Giovanni

AU - Grønvold, Mogens

AU - Snyder, Claire

AU - Gotay, Carolyn

AU - Fallowfield, Dame Lesley

AU - Apostolidis, Kathi

AU - Wilson, Roger

AU - Stephens, Richard

AU - Schünemann, Holger

AU - Calvert, Melanie

AU - Holzner, Bernhard

AU - Musoro, Jammbe Z.

AU - Wheelwright, Sally

AU - Martinelli, Francesca

AU - Dueck, Amylou C.

AU - Pe, Madeline

AU - Coens, Corneel

AU - Velikova, Galina

AU - Kuliś, Dagmara

AU - Taphoorn, Martin J.B.

AU - Darlington, Anne Sophie

AU - Lewis, Ian

AU - van de Poll-Franse, Lonneke

PY - 2019/11

Y1 - 2019/11

N2 - The 5th EORTC Quality of Life in Cancer Clinical Trials Conference presented the current state of quality of life and other patient-reported outcomes (PROs) research from the perspectives of researchers, regulators, industry representatives, patients and patient advocates and health care professionals. A major theme was the assessment of the burden of cancer treatments, and this was discussed in terms of regulatory challenges in using PRO assessments in clinical trials, patients’ experiences in cancer clinical trials, innovative methods and standardisation in cancer research, innovative methods across the disease sites or populations and cancer survivorship. Conferees demonstrated that PROs are becoming more accepted and major efforts are ongoing internationally to standardise PROs measurement, analysis and reporting in trials. Regulators are keen to collaborate with all stakeholders to ensure that the right questions are asked and the right answers are communicated. Improved technology and increased flexibility of measurement instruments are making PROs data more robust. Patients are being encouraged to be patient partners. International collaborations are essential, because this work cannot be accomplished on a national level.

AB - The 5th EORTC Quality of Life in Cancer Clinical Trials Conference presented the current state of quality of life and other patient-reported outcomes (PROs) research from the perspectives of researchers, regulators, industry representatives, patients and patient advocates and health care professionals. A major theme was the assessment of the burden of cancer treatments, and this was discussed in terms of regulatory challenges in using PRO assessments in clinical trials, patients’ experiences in cancer clinical trials, innovative methods and standardisation in cancer research, innovative methods across the disease sites or populations and cancer survivorship. Conferees demonstrated that PROs are becoming more accepted and major efforts are ongoing internationally to standardise PROs measurement, analysis and reporting in trials. Regulators are keen to collaborate with all stakeholders to ensure that the right questions are asked and the right answers are communicated. Improved technology and increased flexibility of measurement instruments are making PROs data more robust. Patients are being encouraged to be patient partners. International collaborations are essential, because this work cannot be accomplished on a national level.

KW - Cancer patients

KW - Cancer survivorship

KW - Cancer treatment

KW - Patient-reported outcomes

KW - Quality of life

KW - Symptom assessments

UR - http://www.scopus.com/inward/record.url?scp=85072582660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072582660&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2019.08.016

DO - 10.1016/j.ejca.2019.08.016

M3 - Article

C2 - 31561134

AN - SCOPUS:85072582660

VL - 121

SP - 55

EP - 63

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -